Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | HPD | P32754 | 2/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 7/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.37 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1051521 | 0.92 | HPD (0.39) | FABP3FABP4FABP5HPDPTGER1 | |
| SCHEMBL1053508 | 0.89 | FABP3 (0.43) | FABP3FABP4FABP5HPDPTGER1 | |
| SCHEMBL416210 | 0.88 | FABP3 (0.42) | FABP3FABP4FABP5HPDPTGER1 | |
| SCHEMBL1053901 | 0.87 | FABP3 (0.41) | FABP3FABP4FABP5HPDPTGER1 | |
| SCHEMBL1053819 | 0.87 | FABP3 (0.41) | FABP3FABP4FABP5HPDPTGER1 | |
| SCHEMBL1051458 | 0.81 | MAP2K1 (0.43) | PTGER1SGMS2 | |
| SCHEMBL1053834 | 0.80 | FABP3 (0.53) | FABP3FABP4FABP5PTGER1CYP2C9 | |
| SCHEMBL412466 | 0.79 | BRAF (0.49) | PTGER1CYP2C9CYP2C19CYP1A2TBXA2R | |
| SCHEMBL1053363 | 0.78 | CYP2C9 (0.41) | PTGER1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1054297 | 0.77 | SGMS2 (0.46) | CYP2C19CYP1A2CYP3A4SGMS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101641351-A | Compounds and methods for kinase modulation and indications therefor | PLEXXIKON INC US | 2010-02-03 | — | — | CN | claimed |
| EP-2094701-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-09-02 | — | — | EP | claimed |
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-09-11 | — | — | US | claimed |
| WO-2008080001-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| WO-2008080015-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| US-7872018-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| CN-101641351-A | Compounds and methods for kinase modulation and indications therefor | PLEXXIKON INC US | 2010-02-03 | — | — | CN | disclosed |
| EP-2094701-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| WO-2008080001-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | FABP3 2830/4885FABP4 4576/4885FABP5 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.